ES2100520T3 - Inhibidor de re-estenosis despues de la arterioplastia coronaria percutanea. - Google Patents

Inhibidor de re-estenosis despues de la arterioplastia coronaria percutanea.

Info

Publication number
ES2100520T3
ES2100520T3 ES93901553T ES93901553T ES2100520T3 ES 2100520 T3 ES2100520 T3 ES 2100520T3 ES 93901553 T ES93901553 T ES 93901553T ES 93901553 T ES93901553 T ES 93901553T ES 2100520 T3 ES2100520 T3 ES 2100520T3
Authority
ES
Spain
Prior art keywords
percutaneous coronary
substituted
alkyl
alternatively
combined together
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93901553T
Other languages
English (en)
Inventor
Kazuhisa Kodama
Atsushi Hirayama
Hiroyuki Masayasu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2100520T3 publication Critical patent/ES2100520T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

UN INHIBIDOR ESCASAMENTE TOXICO Y EXCELENTE PARA RESTENOSIS, DESPUES DE ARTERIOPLASTIA CORONARIA PERCUTANEA, CONTENIENDO COMO INGREDIENTE ACTIVO UN COMPUESTO REPRESENTADO POR LA FORMULA (1) O (1'') DE UNA SAL DEL MISMO FISIOLOGICAMENTE ACEPTABLE, DONDE R1 Y R2 REPRESENTAN CADA UNO INDEPENDIENTEMENTE HIDROGENO, HALOGENO, TRIFLUOROMETILO, NITRO, ALQUILO DE C1 COXI DE C1 -C6, O ALTERNATIVAMENTE R1 Y R2 SE COMBINAN JUNTAMENTE PARA FORMAR METILENEDIOXI; R3 REPRESENTA ARILO, HETEROCICLO AROMATICO, CICLOALQUILO DE 5 A 7 CARBONOS, O CICLOALKENILO DE 5 A 7 CARBONOS, CADA UNO DE LOS CUALES PUEDE SER SUSTITUIDO; R4 REPRESENTA HIDROGENO, HIDROXI, S INO ACILO) O ARALQUILO, DONDE EL GRUPO ARILO PUEDE SER SUSTITUIDO; R5 REPRESENTA HIDROGENO O C1 C6 ALKILO, O ALTERNATIVAMENTE R4 Y R5 SE COMBINAN JUNTAMENTE PARA FORMAR UN SOLO ENLACE; Y REPRESENTA OXIGENO O AZUFRE; N REPRESENTA UN NUMERO ENTERO ENTRE 0 Y 5; Y EL ATOMO DE SELENIO PUEDE OXIDARSE.
ES93901553T 1992-01-17 1993-01-14 Inhibidor de re-estenosis despues de la arterioplastia coronaria percutanea. Expired - Lifetime ES2100520T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP655292 1992-01-17

Publications (1)

Publication Number Publication Date
ES2100520T3 true ES2100520T3 (es) 1997-06-16

Family

ID=11641498

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93901553T Expired - Lifetime ES2100520T3 (es) 1992-01-17 1993-01-14 Inhibidor de re-estenosis despues de la arterioplastia coronaria percutanea.

Country Status (11)

Country Link
US (1) US5480888A (es)
EP (1) EP0622076B1 (es)
JP (1) JPH05255084A (es)
KR (1) KR100214453B1 (es)
AT (1) ATE150964T1 (es)
CA (1) CA2126465C (es)
DE (1) DE69309435T2 (es)
DK (1) DK0622076T3 (es)
ES (1) ES2100520T3 (es)
GR (1) GR3023308T3 (es)
WO (1) WO1993013762A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5847007A (en) 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
AU5513796A (en) * 1995-04-25 1996-11-18 Daiichi Pharmaceutical Co., Ltd. Remedy for acquired immunodeficiency syndrome
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
CA2223595C (en) * 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
TW565558B (en) 1995-11-09 2003-12-11 Chugai Pharmaceutical Co Ltd Intimal thickening inhibitory agent
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
AU3457300A (en) 1999-03-31 2000-10-16 Daiichi Pharmaceutical Co., Ltd. Substrates for thioredoxin reductase
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7776925B2 (en) * 2002-03-06 2010-08-17 Duke University Reversing, postponing or preventing the occurrence of GTN tolerance and/or generation of reactive oxygen species from mitochondria
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3407511A1 (de) * 1984-03-01 1985-09-05 A. Nattermann & Cie GmbH, 5000 Köln Benzisoselenazolthione, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
EP0165534B1 (de) * 1984-06-22 1989-03-15 A. Nattermann & Cie. GmbH S-(Carbamoyl-phenylselenyl)-Derivate des Glutathions und von Aminomercaptocarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
DE3422962A1 (de) * 1984-06-22 1986-01-02 A. Nattermann & Cie GmbH, 5000 Köln Glutathion-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3443467A1 (de) * 1984-11-29 1986-05-28 A. Nattermann & Cie GmbH, 5000 Köln Mercaptanderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3663139D1 (en) * 1985-04-12 1989-06-08 Nattermann A & Cie Diseleno-bis-benzamides of primary and secondary amines, processes for their production and pharmaceutical preparations containing them
DE3626554A1 (de) * 1986-08-06 1988-02-18 Nattermann A & Cie Diselenobis-benzoesaeureamide primaerer heterocyclischer amine, verfahren zur ihrer herstellung und diese enthaltende pharmazeutische praeparate
JP2710633B2 (ja) * 1987-08-28 1998-02-10 第一製薬株式会社 心臓疾患治療剤
JP2596970B2 (ja) * 1988-05-23 1997-04-02 第一製薬株式会社 白血球の粘着又は凝集抑制剤
US5187105A (en) * 1988-07-01 1993-02-16 Miles Inc. Process for determining thiols using chromogenic benzoisothiazolone derivatives
DE3937169A1 (de) * 1989-11-08 1991-05-16 Nattermann A & Cie Benzylselenobenzamide von anilinen und benzylaminen

Also Published As

Publication number Publication date
DE69309435D1 (de) 1997-05-07
WO1993013762A1 (fr) 1993-07-22
US5480888A (en) 1996-01-02
ATE150964T1 (de) 1997-04-15
EP0622076A4 (en) 1994-12-21
EP0622076B1 (en) 1997-04-02
DK0622076T3 (da) 1997-06-02
CA2126465A1 (en) 1993-07-22
DE69309435T2 (de) 1997-07-10
JPH05255084A (ja) 1993-10-05
GR3023308T3 (en) 1997-08-29
EP0622076A1 (en) 1994-11-02
KR100214453B1 (ko) 1999-08-02
CA2126465C (en) 2002-03-05

Similar Documents

Publication Publication Date Title
ES2100520T3 (es) Inhibidor de re-estenosis despues de la arterioplastia coronaria percutanea.
LU91210I2 (fr) Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
FI953968A0 (fi) Antraniiliset happojohdannaiset
DE69736642D1 (de) Heterocyclische Verbindungen, ihre Herstellung und Verwendung
FI943561A0 (fi) Uudet ainekoostumukset
DE68906183D1 (de) 2'-desoxy-5-fluoruridinderivate.
NO306992B1 (no) Quinolinderivater, farmasoeytiske preparater inneholdende forbindelsene og anvendelsen av forbindelsene
DE69935718D1 (de) Antidiabetische medikamente
DE69215694D1 (de) Benzamid-derivate
DE69229637D1 (de) Oxazolidone Derivative als Monoamine-Oxidaseinhibitoren
NZ221699A (en) Pyridazinone derivatives; pharmaceutical compositions and intermediates
ATE240949T1 (de) Epoxysuccinamid-derivate oder ihre salze
ATE214059T1 (de) 4,6-di-t-butyl-2,3-dihydrobenzothiophene, die ldl oxidation hemmen
ATE205209T1 (de) Chinolincarbonsäurederivate und ihre salze
ES2155655T3 (es) Compuestos de benzotiofeno, usos y formulaciones de los mismos.
ATE285240T1 (de) Verwendung von sulfoquinovosyldiacylglycerol derivativen als immunosuppresssiva
ATE192141T1 (de) Aromatische hydroxamsäure-verbindungen, ihre herstellung und verwendung
NO903084D0 (no) Farmasoeytisk anvendbare thiazol-derivater og fremgangsmaate for deres fremstilling.
DE69314929D1 (de) Benzolderivate
DE69220371D1 (de) Hemmstoff der blutgefässhypertrophie
TH13795A (th) อนุพันธ์กวานิดีน

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 622076

Country of ref document: ES